SIDP Works with NIH on Revised COVID-19 Treatment Guidelines
The National Institutes of Health (NIH) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines issued a second update on June 11, 2020, available here.
The revised COVID-19 guidelines include new sections on pediatrics, SARS-CoV-2 testing, and acute kidney injury, as well as updated recommendations for the use of potential antiviral drugs. The expanded recommendations on the use of remdesivir reflect information from the latest published clinical trials. This clarifies use in hospitalized patients with severe disease and outlines considerations for duration of therapy. The panel has also updated the recommendation on the use of chloroquine or hydroxychloroquine, recommending against use for treatment of COVID-19 except in the setting of clinical trials.
“New data on the management of COVID-19 is published at an unprecedented pace, and the NIH COVID-19 Guidelines have been nimble and flexible to incorporate updated and reliable information in a timely manner. This is essential support for front line clinicians who are primarily focused on caring for these patients,” said SIDP President Jason Pogue.
The Society of Infectious Diseases Pharmacists (SIDP) is represented on the NIH COVID-19 Guideline Panel by Susan Davis, SIDP President-Elect.
Please visit sidp.org/covid-19 for additional educational offerings and resources from SIDP related to COVID-19.Bottom of Form
SIDP is an association of pharmacists and allied healthcare professionals dedicated to promoting the appropriate use of antimicrobial agents. SIDP membership is comprised of 1,500 members in hospital, academic, industry, governmental organizations, and other practice settings across all 50 states and throughout the globe. The mission of SIDP is to advance infectious diseases pharmacy and lead antimicrobial stewardship in order to optimize the care of patients.
Phone: (331) 248-7888
121 W. State Street
Geneva, IL 60134